May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Ranibizumab for Macular Edema Due to Retinal Vein Occlusions
Author Affiliations & Notes
  • P. A. Campochiaro
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • S. M. Shah
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • G. Hafiz
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • E. Quinlan
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • I. Zimmer-Galler
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • Q. D. Nguyen
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • D. V. Do
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • H. Ying
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • J. U. Sung
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • Wilmer Retinal Research Group
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • Footnotes
    Commercial Relationships P.A. Campochiaro, Genentech, F; S.M. Shah, None; G. Hafiz, None; E. Quinlan, None; I. Zimmer-Galler, None; Q.D. Nguyen, Genetech, Regeneron, F; D.V. Do, None; H. Ying, None; J.U. Sung, None.
  • Footnotes
    Support Genentech
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1545. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. A. Campochiaro, S. M. Shah, G. Hafiz, E. Quinlan, I. Zimmer-Galler, Q. D. Nguyen, D. V. Do, H. Ying, J. U. Sung, Wilmer Retinal Research Group; Ranibizumab for Macular Edema Due to Retinal Vein Occlusions. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1545.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To compare the effects of multiple injections of 0.3 and 0.5mg of ranibizumab on macular edema in patients with retinalvein occlusions.

 
Methods:
 

Patients with macular edema due to central (CRVO, n=20) or branchretinal vein occlusion (BRVO, n=20) are being randomized 1:1to receive 3 monthly injections of 0.5 or 0.3 mg of ranibizumab.Primary outcome is change in visual acuity from baseline at3 months. Secondary outcomes are change in visual acuity frombaseline at 0.25, 1, 2, 4 and 6 months, and change in central1 mm foveal thickness (FT) at all of the above time points.

 
Results:
 

Twelve patients with BRVO and 14 with CRVO have been randomized.Interim results without regard to treatment assignment, whichis unknown, are: 

 

 
Conclusions:
 

Three intravitreous injections of ranibizumab have been well-toleratedand regardless of dose, preliminary data suggest overall improvementsin VA and foveal thickness. It will be important to determineif there are differences between the treatment groups.

 
Clinical Trial:
 

www.clinicaltrials.gov pending

 
Keywords: vascular occlusion/vascular occlusive disease • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×